Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Introduction: Creatine supplementation has emerged as a promising non-pharmacological therapeutic strategy to counteract muscle dysfunction and low lean mass in a variety of conditions, including in pediatric and rheumatic diseases. The objective of this study was to examine the efficacy and safety of creatine supplementation in childhood systemic lupus erythematosus (C-SLE). Methods: C-SLE patients with mild disease activity ( n = 15) received placebo or creatine supplementation in a randomized fashion using a crossover, double-blind, repeated-measures design. The participants were assessed at baseline and after 12 weeks in each arm, interspersed by an eight-week washout period. The primary outcomes were muscle function, as assessed by a battery of tests including one-maximum repetition (1-RM) tests, the timed-up-and-go test, the timed-stands test, and the handgrip test. Secondary outcomes included body composition, biochemical markers of bone remodeling, aerobic conditioning, quality of life, and physical capacity. Possible differences in dietary intake were assessed by three 24-hour dietary recalls. Muscle phosphorylcreatine content was measured through phosphorus magnetic resonance spectroscopy (31 P-MRS). The safety of the intervention was assessed by laboratory parameters, and kidney function was measured by 51 Cr-EDTA clearance. Additionally, self-reported adverse events were recorded throughout the trial. Results: Intramuscular phosphorylcreatine content was not significantly different between creatine and placebo before or after the intervention (creatine-Pre: 20.5 ± 2.6, Post: 20.4 ± 4.1, placebo-Pre: 19.8 ± 2.0; Post: 20.2 ± 3.2 mmol/kg wet muscle; p = 0.70 for interaction between conditions). In addition, probably as a consequence of the lack of change in intramuscular phosphorylcreatine content, there were no significant changes between placebo and creatine for any muscle function and aerobic conditioning parameters, lean mass, fat mass, bone mass, and quality of life scores ( p > 0.05). The 51 Cr-EDTA clearance was not altered by creatine supplementation and no side effects were noticed. Conclusion: A 12-week creatine supplementation protocol at 0.1 g/kg/d is well tolerated and free of adverse effects but did not affect intramuscular phosphorylcreatine, muscle function, free-fat mass or quality of life in non-active C-SLE patients. Trial registration: Clinicaltrials.gov number: NCT01217320.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, research in adult populations [3,12,13] has indicated a moderate degree of variability in tissue uptake response to creatine supplementation protocols.”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [13]
In the citing paper
“Additionally, it is also worth noting these studies were conducted in patients with childhood-onset systemic lupus erythematosus and juvenile dermatomyositis, which may have influenced the efficacy of creatine supplementation in its ability to increase phosphocreatine content.”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [13]
In the citing paper
“Alternatively, contradictory reports to these outcomes regarding the efficacy of creatine supplementation have indicated little to no impact on intramuscular phosphocreatine content; however the relative dose used in these studies may have been too low (0.1 g/kg/day for 12 weeks) to elicit any meaningful changes in creatine content [12,13].”
From Creatine Supplementation in Children and Adolescents (2021) · cites this paper as [13]
In the citing paper
“Hayashi et al. [81] found improvements in pediatric patients with systemic lupus erythematosus and reported no adverse changes in laboratory parameters of hematology, kidney function, liver function or inflammatory markers after 12 weeks of creatine supplementation.”
From Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show? (2021) · cites this paper as [81]
In the citing paper
“Importantly, the creatine supplementation protocol appeared to be well tolerated and did not adversely affect laboratory markers of kidney function, oxidative stress, and bone health [81–83].”
From Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show? (2021) · cites this paper as [81]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
Podsiadlo, D., & Richardson, S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01616.x · Cited by 14,418
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Variations in the pattern of pubertal changes in boys
Marshall, W. A., & Tanner, J. M. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.239.13 · Cited by 5,147
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX
(2007) · Systemic Lupus Erythematosus · doi:10.1016/b978-0-323-04434-9.50060-9 · Cited by 2,928
Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011
New approaches for interpreting projected bone densitometry data
Professor Carter, D. R., Bouxsein, M. L., & Marcus, R. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070204 · Cited by 1,065
Muscle creatine loading in men
Hultman, E., Soderlund, K., Timmons, J. A., Cederblad, G., & Greenhaff, P. L. (1996) · Journal of Applied Physiology · doi:10.1152/jappl.1996.81.1.232 · Cited by 822
The creatine kinase system and pleiotropic effects of creatine
Wallimann, T., Tokarska-Schlattner, M., & Schlattner, U. (2011) · Amino Acids · doi:10.1007/s00726-011-0877-3 · Cited by 797
Olsen, S., Aagaard, P., Kadi, F., Tufekovic, G., Verney, J., Olesen, J. L., Suetta, C., & Kjær, M. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.107359 · Cited by 319
Research works printed but not linked: 5
- Alsufyani KA, 2005, J Rheumatol, 32, 729
- Kley RA, 2013, Cochrane Database Syst Rev, 6, CD004760
- Gladman DD, 2002, J Rheumatol, 29, 288
- Newcomer KL, 1993, J Rheumatol, 20, 21
- Machado CS, 2001, Clin Exp Rheumatol, 19, S25
Cited by
Antonio, J., Candow, D. G., Forbes, S. C., Gualano, B., Jagim, A. R., Kreider, R. B., Rawson, E. S., Smith-Ryan, A. E., VanDusseldorp, T. A., Willoughby, D. S., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-021-00412-w · Cited by 345
“[81] found improvements in pediatric patients with systemic lupus erythematosus and reported no adverse changes in laboratory parameters of hematology, kidney function, liver function or inflammatory markers after 12 weeks of creatine supplementation.”
BackgroundSelf-citationCreatine Supplementation and Brain Health
Roschel, H., Gualano, B., Ostojic, S. M., & Rawson, E. S. (2021) · Nutrients · doi:10.3390/nu13020586 · Cited by 174
Self-citationDolan, E., Gualano, B., & Rawson, E. S. (2019) · European Journal of Sport Science · doi:10.1080/17461391.2018.1500644 · Cited by 171
“Additionally, creatine supplements are widely available, inexpensive, and have a very good safety profile (Gualano et al., 2011, 2012; Hayashi et al., 2014; Lugaresi et al., 2013; Pereira et al., 2015; Persky & Rawson, 2007; Rawson, Clarkson, & Tarnopolsky, 2017), which also favours the decision to…”
BackgroundSelf-citationCreatine supplementation in the aging population: effects on skeletal muscle, bone and brain
Gualano, B., Rawson, E. S., Candow, D. G., & Chilibeck, P. D. (2016) · Amino Acids · doi:10.1007/s00726-016-2239-7 · Cited by 133
“…supplementation (20 g day−1 for 5 days + 5 g day−1 for 161 days) on CTX or P1NP in postmenopausal women (Gualano et al. 2014), and no effects of 0.1 g kg−1 g day−1 creatine for 12 weeks on CTX or P1NP in children and teenagers with childhood systemic lupus erythematosus (Hayashi et al. 2014).”
BackgroundMethodInfluentialSelf-citationHall, C. H. T., Lee, J. S., Murphy, E. M., Gerich, M. E., Dran, R. J., Glover, L. E., Abdulla, Z. I., Skelton, M. R., & Colgan, S. P. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.033 · Cited by 103
Metadata
- Authors
- Hayashi, A. P., Solis, M. Y., Sapienza, M. T., Otaduy, M. C. G., de Sá Pinto, A. L., Silva, C. A., Sallum, A. M. E., Pereira, R. M. R., & Gualano, B.
- Affiliations
- School of Medicine
- Universidade de São Paulo (BR)
- Corresponding author
- Gualano, B
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2014-08-18
- Volume
- 23
- Issue
- 14
- Pages
- 1500-1511
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2074188667
- Cited by
- 35
- References
- 51
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Keywords
- creatine supplementation, pediatric lupus, muscle function, lean body mass, body composition, bone remodeling, aerobic conditioning, quality of life, renal function, safety, pediatric rheumatic diseases, dietary intake, phosphorus magnetic resonance spectroscopy, Timed Up and Go test, grip strength, 51Cr-EDTA clearance
- MeSH terms
- Adolescent, Body Composition, Child, Creatine, Double-Blind Method, Exercise Test, Female, Humans, Lupus Erythematosus, Systemic, Magnetic Resonance Imaging, Male, Phosphocreatine, Quality of Life, Anaerobic Threshold, Bone Remodeling, Exercise Tolerance, Muscle, Skeletal, Cross-Over Studies, Hand Strength, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial. https://app.cochat.ai/papers/10.1177/0961203314546017
- The paper
- Hayashi, A. P., Solis, M. Y., Sapienza, M. T., Otaduy, M. C. G., de Sá Pinto, A. L., Silva, C. A., Sallum, A. M. E., Pereira, R. M. R., & Gualano, B. (2014). Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial. Lupus. https://doi.org/10.1177/0961203314546017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.